Aerie Pharmaceuticals

Aerie Pharmaceuticals
Traded as NASDAQ: AERI
Russell 2000 Component

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.[1][2][3]

References

  1. ↑ Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
  2. ↑ Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
  3. ↑ "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.